Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CALDOLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CALDOLOR.
ALEVE-D SINUS & COLD vs CALDOLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing synthesis of prostaglandins involved in inflammation, pain, and fever.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
800 mg IV every 8 hours as a 30-minute infusion; alternatively, 400 mg IV every 6 hours. Maximum daily dose: 2400 mg.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
2-4 hours (terminal half-life). Clinical context: Requires dosing every 6-8 hours for sustained effect; no accumulation with normal hepatic function.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal (primarily as glucuronide conjugates and inactive metabolites; <10% unchanged). Biliary/fecal elimination is negligible.
Category C
Category C
NSAID/Decongestant Combination
NSAID